Molecular aspects of pituitary tumorigenesis;Aspectos moleculares da tumorigênese hipofisária

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 4, 2008, Pages 599-610

  Pinto, Emilia Modolo ^a   Bronstein, Marcello D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Oncogenes; Pituitary tumors; Suppressor tumor; Tumorigenesis

Indexed keywords

EID: 47249122247     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000400005     Document Type: Review

References (73)

1. Sonabend AM, Musleh W, Lesniak MS. Oncogenesis and mutagenesis of pituitary tumors. Expert Rev Anticancer Ther. 2006;6 Suppl 9:S3-14.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
3. Cairns J. The origin of human cancers. Nature. 1981;289 (5796):353-7.
4. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog. 1993;7(3):139-46.
5. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-60.
6. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349-52.
7. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science. 2002;297(5581):565-9.
8. Bishop JM. Viral oncogenes. Cell. 1985;42(1):23-38.
9. Herman V Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990;71(6):1427-33.
10. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev. 1998;19(6):798-827.
11. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961;190:372-3.
12. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science. 1996;274(5293):1664-72.
13. Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmüller L, Deppert W. Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene. 1999;18(53):7706-17.
14. El-Deiry WS. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol. 1998;227:121-37.
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51(23 Pt 1):6304-11.
16. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997;11(4):433-41.
17. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1999;13(1):156-66.
18. Zhang X, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999;84(2):761-7.
19. Zou H Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999;285(5426):418-22.
20. Yu R, Lu W, Chen J, McCabe CJ, Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology. 2003;144(11):4991-8.
21. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, et al. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf). 2003;58(2):141-50.
22. Turner HE, Nagy Z, Sullivan N, Esiri MM, Wass JA. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin Endocrinol (Oxf). 2000;53(3):337-44.
23. Nickeleit I Zender S, Kossatz U, Malek NP. p27kip1: a target for tumor therapies? Cell Div. 2007;2:13.
24. Lloyd RV Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol. 1997;150(2):401-7.
25. Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol. 1997;151(2):509-19.
26. Bamberger A, Sudahl S, Bamberger CM, Schulte HM, Löning T. Expression patterns of the cell-cycle inhibitor p27 and the cell-cycle promoter cyclin E in the human placenta throughout gestation: implications for the control of proliferation. Placenta. 1999;20(5-6):401-6.
27. Tanaka C, Yoshimoto K, Yang P, Kimura T, Yamada S, Moritani M, et al. Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J Clin Endocrinol Metab. 1997; 82(9):3141-7.
28. Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, Lowe DG, et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin- secreting tumours. Oncogene. 1998;16(1):69-76.
29. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(42):15558-63.
30. Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M, et al. CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol. 2001;193(4):491-7.
31. Jaffrain-Rea ML, Ferretti E, Toniato E, Cannita K, Santoro A, Di Stefano D, et al. p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clin Endocrinol (Oxf). 1999;51(3):317-25.
32. Yoshimoto K, Tanaka C, Yamada S, Kimura T, Iwahana H, Sano T, Itakura M. Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary adenomas. Eur J Endocrinol. 1997;136(1):74-80.
33. Bishop JM. Molecular themes in oncogenesis. Cell. 1991;64(2):235-48.
34. Medema RH, de Vries-Smits AM, van der Zon GC, Maassen JA, Bos JL. Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21ras. Mol Cell Biol. 1993;13(1):155-62.
35. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7(2):79-94.
36. Marshall CJ. Tumor suppressor genes. Cell. 1991. 64(2):313-26.
37. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122(3):135-40.
38. Meng RD, Shih H, Prabhu NS, George DL, el-Deiry WS. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res. 1998;4(1):251-9.
39. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-10.
40. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res. 1997;71:1-25.
41. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9(6):1799-805.
42. Janus F, Albrechtsen N, Dornreiter I, Wiesmüller L, Grosse F, Deppert W. The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci. 1999;55(1):12-27.
43. Donangelo I, Araújo PB, Antenuzi D, Farage M, Marcondes J, Filho PN, Gadelha MR. Tumor deletion mapping of chromosomal region 13q14 in 43 growth hormone secreting pituitary adenomas. Endocrine. 2005;28(2):131-6.
44. Takino H, Herman V, Weiss M, Melmed S. Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab. 1995;80(5):1733-8.
45. Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf). 1996;45(2):195-200.
46. Bates AS, Buckley N, Boggild MD, Bicknell EJ, Perrett CW, Broome JC, Clayton RN. Clinical and genetic changes in a case of a Cushing's carcinoma. Clin Endocrinol (Oxf). 1995;42(6):663-70; discussion 671-2.
47. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55(20):525-30.
48. LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab. 1996;81(2):656-62.
49. Abbass SA, Asa SL, Ezzat S. Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab. 1997;82(4):1160-6.
50. Thakker RV, Pook MA, Wooding C, Boscaro M, Scanarini M, Clayton RN. Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations. J Clin Invest. 1993;91(6):2815-21.
51. Bronstein MD, Melmed S. Pituitary tumorigenesis. Arq Bras Endocrinol Metabol. 2005;49(5):615-25.
52. Hui AB, Pang JC, Ko CW, Ng HK. Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization. Hum Pathol. 1999;30(9):1019-23.
53. Scheithauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol. 1987;4(3):205-11.
54. Yen RS, Allen B, Ott R, Brodsky M. The syndrome of right atrial myxoma, spotty skin pigmentation, and acromegaly. Am Heart J. 1992;123(1):243-4.
55. Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kastner DL, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest. 1996;97(3):699-705.
56. Casey M, Mah C, Merliss AD, Kirschner LS, Taymans SE, Denio AE, et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation. 1998;98(23):2560-6.
57. Gadelha MR, Prezant TR, Une KN, Glick RP, Moskal SF 2nd, Vaisman M, et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab. 1999;84(1):249-56.
58. Toledo RA, Lourenço DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab. 2007;92(5):1934-7.
59. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92(5):1891-6.
60. Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C, Magalhães AV, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol. 2007;157(4):383-91.
61. Berezin M, Karasik A. Familial prolactinoma. Clin Endocrinol (Oxf). 1995;42(5):483-6.
62. Shimon I, Hinton DR, Weiss MH, Melmed S. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness. Clin Endocrinol (Oxf). 1998;48(1):23-9.
63. Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest. 2002;109(2):277-83.
64. Friedman E, Adams EF, Höög A, Gejman PV, Carson E, Larsson C, et al. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab. 1994;78(3):568-74.
65. Ben-Shlomo A, Miklovsky I, Ren SG, Yong WH, Heaney AP, Culler MD, Melmed S. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. J Clin Endocrinol Metab. 2003;88(2):858-63.
66. Missale C, Fiorentini C, Finardi A, Spano P. Growth factors in pituitary tumors. Pituitary. 1999;1(3-4):153-8.
67. Giacomini D, Páez-Pereda M, Theodoropoulou M, Gerez J, Nagashima AC, Chervin A, et al. Bone morphogenetic protein-4 control of pituitary pathophysiology. Front Horm Res. 2006;35:22-31.
68. Trautmann K, Thakker RV, Ellison DW, Ibrahim A, Lees PD, Harding B, et al. Chromosomal aberrations in sporadic pituitary tumors. Int J Cancer. 2001;91(6):809-14.
69. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol. 2000;143(1):R1-6.
70. Bamberger CM, Fehn M, Bamberger AM, Lüdecke DK, Beil FU, Saeger W, Schulte HM. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol. 1999;140(3):250-5.
71. Simpson DJ, McNicol AM, Murray DC, Bahar A, Turner HE, et al. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin Cancer Res. 2004;10(5):1780-8.
72. Daniely M, Aviram A, Adams EF, Buchfelder M, Barkai G, Fahlbusch R, et al. Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. J Clin Endocrinol Metab. 1998;83(5):1801-5.
73. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, Farrell WE. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res. 1999;5(8):2133-9.